Clinical Supplies Management: From Manufacturer to Site

Clinical supplies management coordinates the investigational product, comparator medicines and ancillary materials a study needs, from manufacturing release through depot storage, clinical-site dispensing and final reconciliation. The challenge is to keep each shipment aligned with the protocol, product-specific conditions and participant demand while preserving a traceable record of what moved, where it went and what happened to it.

For sponsors and CROs, a useful way to manage the clinical supply chain is to follow the product's entire journey, including the return journey. A shipment delivered on time is only one part of the process. Site readiness, controlled storage, product accountability and decisions about unused stock are equally important.

What is clinical supplies management?

Clinical supplies management is the planning, sourcing, packaging, inventory control, distribution and accountability of materials used in a clinical study. These clinical trial supplies can include the investigational product (IP), matching placebo or comparator medicines, dispensing materials, administration devices and protocol-specific ancillary kits. The exact scope depends on what the study requires and how each item is regulated.

The sponsor coordinates the overall supply strategy. Manufacturers and packaging facilities prepare products and kits, while depots, couriers, pharmacies and investigator sites carry out defined parts of the physical flow. In a US investigational new drug (IND) study, investigators must control access to investigational drugs and document their disposition under 21 CFR 312.61 and 312.62. Responsibilities cannot be transferred away merely by hiring a shipping provider.

What are the steps in the clinical trial supply chain?

The clinical trial supply management process begins with protocol-driven forecasting, moves through manufacturing and release, comparator sourcing, kit packaging, depot storage, site distribution, dispensing, and inventory reconciliation. Unused supplies are returned or destroyed under authorization, with accountability and temperature records maintained throughout.

The table is a practical workflow, not a universal regulatory checklist. Country rules, product classification, trial design and stability data determine the exact controls. The underlying expectation is that each unit can be traced from release to use or final disposition, as reflected in ICH E6(R3) Good Clinical Practice.

Forecast demand before placing stock

Forecasting uses planned and actual enrollment, treatment-arm allocation, dose changes, visit windows, recruitment variability and lead times. Clinical supplies management depends on an accurate resupply forecast, particularly when a depot serves multiple active sites. The resupply method should respond to actual demand without allowing site stockouts or excessive expiry risk. Some programs use interactive response technology (IRT) to support allocation and resupply, but the system still depends on accurate site inventory and defined responsibility for approving orders.

Clinical supply chain management should account for amendments. A changed dosing schedule or newly opened country may require different kit configurations, additional documentation, revised depot placement or a new transit qualification. Treat changes as a controlled update to demand, product status and shipping instructions, rather than an informal rush order.

Coordinate investigational product, comparator and ancillary supplies

The investigational product can be an unapproved drug or a marketed product being studied under a trial protocol. Comparator and ancillary supplies require their own planning. A comparator may need sourcing, verification, relabeling or blinding. Ancillary items may include infusion sets, syringes, collection materials, devices, instructions and return packaging. They do not necessarily share the same manufacturing, release or storage requirements as the IP.

Where kits contain multiple items, the right quantity and configuration must reach the intended site or participant at the scheduled time. For a deeper look at protocol-specific assembly and labeling, see Mercury's clinical trial kit-building guide. Comparator sourcing strategy should also consider country availability, traceability and how changes could affect study blinding.

How are investigational products shipped to clinical sites?

Investigational product shipping to clinical sites begins with a release-to-ship decision: confirm the intended recipient is authorized, the product is eligible for distribution, the quantity matches the request and the shipment can meet its approved transport conditions. The shipper then prepares the packaging, documents and tracking needed for the route. At arrival, trained site staff check and record receipt before product enters usable inventory.

The same principle applies to clinical trial supply logistics across borders, with added attention to import authorization, product classification, customs documents, language and destination-specific handling rules. Customs clearance time belongs in the shipping plan, especially when a temperature-controlled parcel could outlast its qualified holding time.

Depot-to-site distribution and accountable receipt

Depot-to-site distribution helps position inventory near active investigators. A regional depot can hold study stock, fulfill approved resupply orders and document what was dispatched. The receiving site then checks package condition, seal integrity where applicable, contents, quantities, identifiers and temperature information against its instructions. Any damaged, unidentified or potentially compromised product should be segregated pending the sponsor's or designated quality function's decision.

A practical pre-dispatch check includes:

1. Confirm protocol, site authorization, product/kit identity, lot, expiry and permitted quantity.

2. Verify packaging qualification for the required conditions, route and planned delay allowance.

3. Prepare the appropriate shipment, customs and handling documents without disclosing blinded allocation.

4. Confirm the receiving site's delivery window, storage capability and escalation contacts.

5. Define where the receipt and temperature records will be reviewed and who can release quarantined stock.

These checks create an auditable handoff. They also help distinguish a physical delivery confirmation from the site's decision that product is suitable for dispensing.

How do you prevent temperature excursions for clinical trial supplies?

Temperature-controlled clinical trial shipments need a product-specific transport range supported by stability information, a qualified packaging configuration, a suitable route and evidence of conditions during movement. No single temperature band applies to every investigational drug. The required range may be ambient, refrigerated, frozen or cryogenic, depending on the material.

Prevention starts with lane risk assessment. Consider ambient extremes, flight transfers, weekend holds, customs delays, packaging conditioning, logger placement and how long the site may take to unpack a delivery. Pair validated packaging with calibrated or otherwise qualified monitoring appropriate to the risk. Mercury's end-to-end cold-chain guide goes deeper on shipping configurations and monitoring.

A temperature excursion is a signal to investigate, not automatic proof that a product is unusable. If monitoring shows an out-of-range event, isolate the affected stock where instructed, preserve the temperature record, record duration and severity, notify the designated sponsor/quality contacts and obtain a documented disposition decision based on relevant stability data. Do not release or destroy stock solely because a courier dashboard issued an alert. This approach is consistent with Health Canada's temperature-control guidance.

Where does direct-to-patient clinical trial shipping fit?

Direct-to-patient clinical trial shipping can supplement site distribution when the protocol, product characteristics and applicable jurisdiction permit it. Supply may travel from a depot, pharmacy or other authorized location to a participant or caregiver. The process needs clear authorization, privacy protection, instructions for receipt and storage, a realistic delivery window and a way to document the product's onward use and accountability.

Direct delivery is especially sensitive when the product requires supervised administration, preparation, special storage or an immediate clinical assessment. The decision belongs in the study's risk assessment and clinical oversight arrangements, not simply in courier routing. The FDA's September 2024 decentralized-trials guidance discusses implementation of remote trial activities. Mercury covers the operational detail in its direct-to-patient logistics guide.

ICH E6(R3) Annex 2 also addresses shipment to participants and related safeguards. In the EU, Annex 2 is scheduled to become effective on 15 January 2027. It is not yet in effect there as of October 2026. See the EMA's E6(R3) status and implementation dates.

What happens to unused clinical trial supplies?

Returns and destruction of unused clinical supplies begin with reconciliation. The site establishes what it received, dispensed, administered, has on hand and returned, identifying unexplained differences before final disposition. Unused or expired investigational drugs must remain under controlled status until an authorized instruction specifies return, destruction or another permitted route.

For US IND studies, 21 CFR 312.59 requires the sponsor to ensure return of unused investigational drug supplies from investigators whose participation ends, or authorize an alternative disposition that does not expose humans to risk. 21 CFR 312.62 addresses investigator disposition records. Procedures can differ by country and product, so a globally uniform destruction decision should never be assumed.

A closeout record should distinguish three different return streams:

• Unused investigational product: reconcile controlled stock and follow sponsor-authorized return or alternative disposition, documenting the decision and quantities.

• Reusable transport assets: recover shippers and data loggers for inspection, cleaning, requalification where needed and separate reuse decisions.

• Biological samples and other materials: follow their own classification, containment and disposal or return requirements, which may differ from investigational drug rules.

Those streams are often combined operationally under reverse logistics, but they should not be treated as the same regulated material. Mercury's reverse logistics guide for clinical trial kits covers return-packaging and asset-recovery planning in more detail.

Making clinical supply services work across the full study

Effective clinical supplies management also depends on clearly assigned decisions: clinical operations, pharmacy, manufacturing, quality and transport teams must agree who authorizes release, dispatch, receipt, deviation handling and returns. Inventory systems can improve visibility, but source records and approval responsibilities still matter. The relevant questions are whether stock is ready, whether a site or participant can receive it and whether every movement can be reconciled later.

Mercury describes temperature-controlled transport, customs coordination, shipment tracking and clinical-material deliveries on its clinical trial logistics services page. Those shipping functions support the wider clinical supply chain. Manufacturing authorization, comparator procurement, clinical dispensing and final investigational-product disposition remain with the appropriately qualified and authorized parties defined by the study and applicable rules.